Inventiva News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

30.09.19	Inventiva completes a capital increase of € 625,000 subscribed by Sofinnova Partners through Sofinnova Crossover I Fund (GlobeNewswire)
26.09.19	Inventiva receives FDA Fast Track designation for lead asset lanifibranor in NASH (GlobeNewswire)
25.09.19	Inventiva: H1 2019 financial results and corporate business update (GlobeNewswire)
19.09.19	Inventiva completes a capital increase of € 8.2 million subscribed by leading US and European biotech investors (GlobeNewswire)
10.09.19	Inventiva announces the positive recommendation of the 4th and last DSMB of the Phase IIb clinical study with lanifibranor in NASH (GlobeNewswire)
04.09.19	Inventiva achieves a major milestone by completing patient recruitment for its Phase IIb clinical study with lanifibranor in NASH (GlobeNewswire)
02.09.19	Odiparcil development advances with recruitment of first patients in a new biomarker study in MPS VI children and adults (GlobeNewswire)
28.08.19	Inventiva secures a new European patent strengthening and extending the protection of its lead product candidate lanifibranor (GlobeNewswire)
26.08.19	Inventiva - New promising results on lanifibranor to be presented at The Liver Meeting® 2019 (GlobeNewswire)
30.07.19	Inventiva - H1 2019 Financial Information and Corporate Business Update (GlobeNewswire)
09.07.19	Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux (GlobeNewswire)
13.06.19	Inventiva announces the creation of its Scientific Advisory Board (GlobeNewswire)
11.06.19	Inventiva Announces End of Patient Recruitment for its Phase IIa Trial in the Treatment of MPS VI (GlobeNewswire)
29.05.19	Nawal Ouzren and Heinz Maeusli appointed to Inventiva’s Board of Directors (GlobeNewswire)
24.05.19	Inventiva to Present at the Jefferies 2019 Healthcare Conference (GlobeNewswire)
23.05.19	Repeat: Inventiva announces that FDA lifts target class clinical hold which allows long-term clinical studies with lanifibranor in NASH (GlobeNewswire)
23.05.19	Inventiva announces that FDA lifts target class clinical hold which allows long-term clinical studies with lanifibranor in NASH (GlobeNewswire)
15.05.19	Q1 2019 Financial Information and Corporate Business Update (GlobeNewswire)
23.04.19	Inventiva to present new results of its YAP-TEAD oncology program at the AACR Special Conference on The Hippo Pathway (GlobeNewswire)
05.03.19	INVENTIVA : The FDA Grants Rare Pediatric Disease Designation to Odiparcil for the Treatment of MPS VI (GlobeNewswire)
27.02.19	INVENTIVA: 2018 Full-Year Results : Important Progress in R&D Portfolio and Solid Cash Position (GlobeNewswire)
21.02.19	Inventiva announces further progress achieved in the clinical development of lanifibranor for the treatment of NASH (GlobeNewswire)
04.02.19	INVENTIVA : New results on lanifibranor to be presented at the International Liver Congress 2019 (GlobeNewswire)
10.12.18	Inventiva invited to present at the 37th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
13.11.18	Inventiva: 2018 third quarter financial update (GlobeNewswire)
07.11.18	Inventiva Announces Poster Presentation on Its YAP/TEAD Inhibitor Program at the EORTC-NCI-AACR Symposium in Dublin (GlobeNewswire)
17.10.18	Inventiva announces two appointments to its management team ahead of future key development milestones (GlobeNewswire)
15.10.18	Inventiva Announces Last Visit by Last Patient in its Phase IIb SSc Trial and Second Positive DSMB Review in its Phase IIb NASH Trial with Lanifibranor (GlobeNewswire)
12.10.18	INVENTIVA to Participate in the "ROTH Battle of the NASH Thrones Investor Conference" (GlobeNewswire)
10.10.18	Inventiva Announces Two Poster Presentations at the American College of Rheumatology Conference (GlobeNewswire)
27.09.18	Inventiva: First-half 2018 financial results and business update (GlobeNewswire)
24.09.18	INVENTIVA : Inventiva launches an independent working group to help increase NASH awareness and establish best practices for its treatment (GlobeNewswire)
30.08.18	INVENTIVA advances in the development of lanifibranor with the achievement of three key milestones (GlobeNewswire)
23.08.18	Inventiva S.A.: Sale of Shares (GlobeNewswire)
23.08.18	Inventiva S.A.: Sale of Shares (GlobeNewswire)
22.08.18	Inventiva announces that it has been informed of the modification of the call option agreement concluded by BVF Partners L.P. (GlobeNewswire)
13.08.18	Inventiva's lanifibranor found to have good safety profile following first assessment of carcinogenicity studies' results (GlobeNewswire)
19.07.18	Inventiva Reports First-half 2018 Financial Results and Provides a Corporate Update (GlobeNewswire)
10.07.18	Inventiva Announces Positive DSMB Reviews in both NASH and Systemic Sclerosis Phase IIb Trials with Lanifibranor (GlobeNewswire)
20.06.18	INVENTIVA : FDA Approval of an Investigator Initiated IND Application to Conduct Phase II Study of Lanifibranor in Type 2 Diabetic Patients with Non-Alcoholic Fatty Liver Disease (GlobeNewswire)
04.04.18	INVENTIVA Announces a U.S. Phase II Investigator-Initiated Study with Lanifibranor on Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes (GlobeNewswire)
07.03.18	INVENTIVA : 2017 Full Year Results - Major progress achieved in clinical development and strong cash position (GlobeNewswire)
26.02.18	Inventiva announces positive outcomes of biomarker study measuring intracellular GAGs in leukocytes from MPS VI patients (GlobeNewswire)
07.11.17	Inventiva: Third-Quarter 2017 Financial Information (Businesswire)
17.10.17	Inventiva’s Phase IIb FASST Trial in Systemic Sclerosis with Lanifibranor Completes Enrollment (Businesswire)
26.09.17	Inventiva: First-Half 2017 Results (Businesswire)
18.09.17	Inventiva’s IVA337 Given Generic Name "Lanifibranor”by the World Health Organization (WHO) (Businesswire)
05.09.17	Inventiva Announces Exercise of Option by Boehringer Ingelheim to Jointly Develop Potential New Treatments for Idiopathic Pulmonary Fibrosis (IPF) (Businesswire)
04.09.17	Inventiva and AbbVie Extend Agreement to Discover New Potent Orally-Available Small Molecule ROR? Inverse Agonist Drug Candidates (Businesswire)
29.08.17	Inventiva’s Odiparcil Awarded Orphan Drug Designation for the Treatment of MPS VI by the European Medicines Agency (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Logitech Intl	73.46	1.60 %	K V
Part Grp Hldg	1’311.50	0.92 %	K V
ABB	51.68	0.82 %	K V
Alcon	77.68	0.73 %	K V
CieFinRichemont	128.55	0.71 %	K V
Zurich Insur Gr	558.40	-0.43 %	K V
Swiss Life Hldg	686.40	-0.58 %	K V
Kuehne+Nagel Int	212.10	-0.61 %	K V
Givaudan	3’864.00	-1.13 %	K V
Novartis	91.25	-1.90 %	K V

Nachrichten zu Inventiva SA act ord

Aktien Top/Flop

Meistgelesene Nachrichten